The company that brought you Fraud & Abuse in Sale & Marketing of Drugs and Prescription Drug Pricing presents:

State False Claims

Summit for Pharmaceutical & Life Sciences Companies and Healthcare Providers

Wednesday, May 23, 2007

About

KNOW what new laws are coming down the pipeline.

With the DRA incentivizing states to enact their own False Claims Acts, you need to have the most updated information on what new laws could impact your client, and you need to be prepared for a potential flood of state litigation based on new statutes, in addition to the state FCAs already in existence.

DEFEND against qui tam suits on multiple fronts

Simply knowing what is out there is not enough. You need to develop practical strategies for litigating, defending, and settling qui tam actions involving both state and federal claims. And it’s essential to incorporate new theories of liability and enforcement into your strategic corporate plan.

DEVELOP an effective updated compliance program

With new mandatory compliance provisions in effect, in addition to accounting for new state laws, it is imperative that your compliance programs are revamped to account for these changes to avoid additional penalties and violations on top of costly qui tam litigation.

With all of this in mind, the American Conference Institute has developed this publication from theState False Claims Summit for Pharmaceutical & Life Sciences Companies and Healthcare Providers. Preparing for new legislation is a daunting task and this is the only publication that will give you the most updated and comprehensive information and advice you need regarding the current landscape of state False Claims Acts while you learn your peers and colleagues. You also will benefit from the detailed written materials prepared specifically for this event.

Contents & Contributors

About

KNOW what new laws are coming down the pipeline.

With the DRA incentivizing states to enact their own False Claims Acts, you need to have the most updated information on what new laws could impact your client, and you need to be prepared for a potential flood of state litigation based on new statutes, in addition to the state FCAs already in existence.

DEFEND against qui tam suits on multiple fronts

Simply knowing what is out there is not enough. You need to develop practical strategies for litigating, defending, and settling qui tam actions involving both state and federal claims. And it’s essential to incorporate new theories of liability and enforcement into your strategic corporate plan.

DEVELOP an effective updated compliance program

With new mandatory compliance provisions in effect, in addition to accounting for new state laws, it is imperative that your compliance programs are revamped to account for these changes to avoid additional penalties and violations on top of costly qui tam litigation.

With all of this in mind, the American Conference Institute has developed this publication from theState False Claims Summit for Pharmaceutical & Life Sciences Companies and Healthcare Providers. Preparing for new legislation is a daunting task and this is the only publication that will give you the most updated and comprehensive information and advice you need regarding the current landscape of state False Claims Acts while you learn your peers and colleagues. You also will benefit from the detailed written materials prepared specifically for this event.

Contents & Contributors

FLORIDA FALSE CLAIMS ACT
Mark S. Thomas, Florida Agency for Health Care Administration (Tallahassee, FL)

PROACTIVELY TRACKING STATE LEGISLATIVE EFFORTS AND USING THE RESULTS IN CORPORATE PLANNING
Joy Johnson Wilson, National Conference of State Legislatures (Washington, DC)
Lena Robins, Foley & Lardner LLP (Washington, DC)

PROACTIVELY TRACKING STATE LEGISLATIVE EFFORTS AND USING THE RESULTS IN CORPORATE PLANNING
John Patrick Oroho, Porzio Bromberg & Newman, PC (Morristown, NJ)

ANALYZING THE OIG GUIDELINES FOR EVALUATING STATE FALSE CLAIMS ACTS
Rebecca Rohr, Covington & Burling LLP (Washington, DC)

DEVELOPING COMPLIANT REPORTING REQUIREMENTS TO AVOID TRIGGERING STATE FCA ENFORCEMENT
Frederick Robinson, Fulbright & Jaworski LLP (Washington, DC)

UNIQUE ASPECTS OF THE CALIFORNIA FALSE CLAIMS ACT
Larry Raskin, Office of the Attorney General, State of California, Department of Justice (Sacramento, CA)

CONDUCTING EFFECTIVE INVESTIGATIONS AND DEFENDING ACTIONS IN PARALLEL STATE AND FEDERAL FCA PROCEEDINGS
Robert S. Salcido, Akin, Gump Strauss Hauer & Feld LLP (Washington, DC)
Joseph F. Savage, Jr., Goodwin & Procter LLP (Boston, MA)
John N. Gallo, Sidley Austin LLP (Chicago, IL)

BRACING FOR NEW THEORIES OF LIABILITY UNDER STATE FALSE CLAIMS ACTS
James P. Holloway, Proskauer Rose LLP (Washington, DC)
Carol A. Poindexter, Shook, Hardy & Bacon LLP (Kansas City, MO)

MINIMIZING DAMAGES AND PENALTIES WITH STATE FALSE CLAIMS
Michael M. Mustokoff, Duane Morris LLP (Philadelphia, PA)

REEVALUATING AND DEVELOPING THE COMPANY’S COMPLIANCE PROGRAM IN LIGHT OF THE NEW RULES AND LAWS
Kathleen McDermott, Sonnenschein Nath & Rosenthal LLP (Washington, DC)

REEVALUATING AND DEVELOPING THE COMPANY’S COMPLIANCE PROGRAM IN LIGHT OF THE NEW RULES AND LAWS
T. Jeffrey Fitzgerald, Faegre & Benson LLP (Denver, CO)



DOCUMENT TYPES: PRESENTATIONS AVAILABLE: 0